{"organizations": [], "uuid": "9bc201fea93c466d562e3f26c4bd9480925b0d40", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-azurrx-biopharma-announces-receipt/brief-azurrx-biopharma-announces-receipt-of-required-approvals-to-add-french-clinical-site-for-its-phase-iia-study-of-ms1819-sd-idUSFWN1PD0ON", "country": "US", "domain_rank": 408, "title": "BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-18T15:13:00.000+02:00", "replies_count": 0, "uuid": "9bc201fea93c466d562e3f26c4bd9480925b0d40"}, "author": "", "url": "https://www.reuters.com/article/brief-azurrx-biopharma-announces-receipt/brief-azurrx-biopharma-announces-receipt-of-required-approvals-to-add-french-clinical-site-for-its-phase-iia-study-of-ms1819-sd-idUSFWN1PD0ON", "ord_in_thread": 0, "title": "BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "azurrx biopharma inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News January 18, 2018 / 1:14 PM / in 12 minutes BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD Reuters Staff 1 Min Read \nJan 18 (Reuters) - Azurrx Biopharma Inc: \n* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY \n* AZURRX BIOPHARMA INC - IN PARTNERSHIP WITH MAYOLY SPINDLER, RECEIVED REQUIRED APPROVALS TO ADD A FRENCH SITE TO PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-18T15:13:00.000+02:00", "crawled": "2018-01-18T15:36:28.057+02:00", "highlightTitle": ""}